Heart rate

Biosensors and Nanosensors Propel Towards a $43.5 Billion Global Market by 2028 - BCC Research Analysis Unveiled

Retrieved on: 
Wednesday, January 31, 2024
Wearable, Nanotechnology, Microfluidics, Growth, Internet of things, Research, Nanoparticle, Miniaturization, International finance, Nanosensor, Nano, Environmental monitoring, Integration, Sensor, Biosensor, Nanocomposite, Heart rate, Algorithm, BCC, Artificial intelligence, Geography, Health, Market, Medical imaging

BOSTON, Jan. 31, 2024 /PRNewswire/ -- Biosensors and nanosensors represent cutting-edge technologies that have significantly advanced the landscape of global markets. Biosensors are analytical devices that combine biological components with sensors to detect and quantify specific substances, offering applications in healthcare, environmental monitoring, and more. Nanosensors, operating at the nanoscale, leverage nanotechnology to enhance precision and sensitivity in detecting various analytes. The global market for these technologies is characterized by rapid advancements, fueled by innovations in nanotechnology, IoT integration, and miniaturization. These sensors find extensive application in healthcare diagnostics, environmental monitoring, and various industries. This report delves into the dynamic market trends and technologies shaping the biosensors and nanosensors arena, providing valuable insights into the transformative potential of these innovations on a global scale.

Key Points: 
  • The global market for these technologies is characterized by rapid advancements, fueled by innovations in nanotechnology, IoT integration, and miniaturization.
  • "According to the latest BCC Research study, the demand for Biosensors and Nanosensors: Global Markets and Technologies is estimated to increase from $30.6.0 billion in 2023 to reach $43.5 billion by 2028, at a compound annual growth rate (CAGR) of 7.3% from 2023 through 2028."
  • This comprehensive report delves into the intricate details of the worldwide biosensors and nanosensors market, providing a meticulous analysis categorized by product type, technology, application, and geography.
  • The narrative elucidates the primary drivers propelling the global biosensors and nanosensors market, coupled with regional dynamics and prevailing industry trends.

Product Design Development Services Market to Record a Growth of USD 5.74 billion between 2022 and 2027, Asia to Occupy 46% Market Share - Technavio

Retrieved on: 
Wednesday, January 31, 2024
Growth, Research, USD, Safety, Sample, Surgical instrument, Application, Instrument, Heart rate, Risk, Exclusive, Geography, Medical device

NEW YORK, Jan. 30, 2024 /PRNewswire/ -- The product design development services market is set to grow by USD 5.74 billion from 2022 to 2027 progressing at a CAGR of 9.44% during the forecast period.

Key Points: 
  • NEW YORK, Jan. 30, 2024 /PRNewswire/ -- The product design development services market is set to grow by USD 5.74 billion from 2022 to 2027 progressing at a CAGR of 9.44% during the forecast period.
  • The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment.
  • Countries including China and India has significant growth in various industries such as manufacturing, healthcare, and technology.
  • The APAC product design and development services market is driven by growing demand for innovative, high-quality products and the need to reduce costs and improve efficiency.

AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

Retrieved on: 
Thursday, January 18, 2024
AEON, Clavicle, Patient, Heart rate, Research, PTSD, Post-traumatic stress disorder, AB toxin, Stellate ganglion, OLE, Neck, DSM-IV codes, Torticollis, Safety, INA, DBP, Head, Botulinum toxin, Lidocaine, IND, Ptosis, FDA, Toxicity, Rat, SGB, Acute stress disorder, Data, Week, Anatomy, Pharmaceutical industry

IRVINE, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today presented new clinical and pre-clinical data for ABP-450 in treating cervical dystonia (CD) and posttraumatic stress disorder (PTSD) at TOXINS 2024, a leading conference held by the International Neurotoxin Association (INA) from January 17th - 20th at the Estrel Berlin in Berlin, Germany.

Key Points: 
  • ABP-450 did not appear to increase treatment-related TEAEs at any dose in the study.
  • These results support further investigation of ABP-450 as a treatment option for patients with CD and other movement disorders.
  • “We are excited to announce positive data from the 52-week OLE portion of the Phase 2 study of ABP-450 for CD.
  • The posters presented by AEON at the TOXINS 2024 conference can be accessed on the Events and Presentations page of the Company’s corporate website.

Empire Portfolio Group Welcomes New Orangetheory Fitness Studio in West Caldwell, NJ

Retrieved on: 
Monday, January 29, 2024
Heart rate, Franchising, Empire, Orangetheory Fitness, Newark-Pompton Turnpike, Golden Joystick Awards, News, Film industry

WEST CALDWELL, N.J., Jan. 29, 2024 /PRNewswire/ -- Empire Portfolio Group ("Empire"), a leading Area Developer and Franchisee of Orangetheory® Fitness, the heart rate-based interval training fitness franchise, announced today it will open a new studio centrally located in West Caldwell, NJ at 895 Bloomfield Avenue.

Key Points: 
  • WEST CALDWELL, N.J., Jan. 29, 2024 /PRNewswire/ -- Empire Portfolio Group ("Empire"), a leading Area Developer and Franchisee of Orangetheory® Fitness, the heart rate-based interval training fitness franchise, announced today it will open a new studio centrally located in West Caldwell, NJ at 895 Bloomfield Avenue.
  • Covering 3000 square feet, the state-of-the-art West Caldwell studio will be equipped with the latest cutting-edge equipment, including Orangetheory's renowned coaching and advanced in-studio and wearable fitness technology.
  • Orangetheory Fitness is a rapidly expanding franchise company and a leader in the boutique fitness industry.
  • For more information about the West Caldwell Orangetheory Fitness studio and founding memberships, please call 862-343-5870.

Remimazolam as an Alternative to Propofol in Oral Surgeries

Retrieved on: 
Monday, January 29, 2024
BSI, BIS, Patient, Heart rate, Bradycardia, Intubation, Incidence, EEG, DDS, Fentanyl, Consciousness, PONV, Propofol, Delirium, Remimazolam, Oral and maxillofacial surgery, Movement, Comparison, PSI, Doctor of Philosophy, Arousal, Remifentanil, Hypotension, Vomiting, Blood pressure, Tsurumi University, Dentistry

LAWRENCE, Kan., Jan. 29, 2024 /PRNewswire-PRWeb/ -- Anesthesia Progress – Propofol has been a widely used intravenous sedative for oral and maxillofacial surgeries because of advantages like less postoperative nausea and vomiting (PONV), no air pollution issues, a fast, clean emergence profile, and less emergence delirium. However, propofol has some significant downsides, including cardiovascular depression, injection pain, high fat content, and not being water-soluble. Recently, remimazolam has been suggested as an alternative to propofol in dental procedures because it does not contain similar fat, does not cause injection pain, and does not have cardiovascular depression potential. But is remimazolam as safe and effective as propofol?

Key Points: 
  • Recently, remimazolam has been suggested as an alternative to propofol in dental procedures because it does not contain similar fat, does not cause injection pain, and does not have cardiovascular depression potential.
  • The results of this study show that remimazolam could be considered a suitable alternative to propofol.
  • They go on to note that "remimazolam appears to be a safe alternative to propofol for providing intubated general anesthesia for oral and maxillofacial surgery procedures."
  • Full text of the article, "Comparison of Remimazolam and Propofol for Intubated General Anesthesia for Oral and Maxillofacial Surgery," Anesthesia Progress, Vol.

DeRUCCI Smart Mattress Wins TWICE CES Picks Award 2024

Retrieved on: 
Tuesday, January 23, 2024
Retail, Consumer Electronics, IOT (Internet of Things), Technology, Home Goods, Artificial Intelligence, The Wall Street Journal, Peter Hancock (professor), Heart rate, Sleep, Research, Aromatherapy, Renni Rucci, Artificial intelligence, Health, Temperature, Diet, ABP, CBS-TV, LaTeX, Electronics, Business Insider, Algorithm, TechRadar, TWICE, News, Safety, Conditional sentence, ABC-TV, CES, Yahoo!, CNET, Exercise, Consumer electronics, Internet of things, Consumer Electronics Show

“CES seemed as busy as ever this year and the awards matched this. This year, we received a record amount of entries, and the quality across the board was incredible. Winners should be extremely proud of their achievement -- their product showed true innovation and hugely impressed our judging panel,” said the TWICE Awards’ editorial team.

Key Points: 
  • The DeRUCCI Group https://www.derucci.com , a leading public company and sleep technology brand, announced today that the DeRUCCI T11 Pro Smart Mattress has won the coveted 2024 CES Picks Awards in the TWICE consumer electronics category.
  • DeRUCCI was selected as a TWICE CES 2024 Picks winner based on the impact expected on the Consumer Electronics industry.
  • The TWICE CES 2024 Picks Award recognizes the very best products and solutions on display at CES 2024, with hundreds of products and solutions considered.
  • “Thank you to the entire TWICE CES 2024 Picks Award editorial team!”
    The CES 2024 Picks Award caps off a successful week at the CES Show in Las Vegas, where DeRUCCI was also awarded with the CES 2024 Innovation Awards in two categories and the BIG Innovation Award, and was also featured in top international publications and shows, including the Wall Street Journal, CNET, Forbes, Business Insider, T3, and Techradar, Yahoo!

InventHelp Inventor Develops Patient Identification & Vitals Scanner (JMT-277)

Retrieved on: 
Friday, January 26, 2024
Multimedia, Sale, Suite, Heart rate, Medical imaging

View original content to download multimedia:https://www.prnewswire.com/news-releases/inventhelp-inventor-develops-pa...

Key Points: 
  • My design enables you to collect patient identification and vital sign information in real-time."
  • The patent-pending invention provides a digital electronic device to verify a patient's identity.
  • It would also acquire essential vital sign data for the patient in a real-time manner.
  • 22-JMT-277, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext.

Blue Spark Technologies Launches Innovative Multi-Vital Remote Patient Monitoring Platform - VitalTraq™

Retrieved on: 
Thursday, January 25, 2024
Cloud, Patient, SCOPE, Fever, Collection, Temperature, Android, Google Cloud Platform, Ecosystem, Safety, Heart rate, Blood pressure, Sepsis, FDA, Vital signs, Respiratory rate, IOS, CE, Medical device

CLEVELAND, Jan. 25, 2024 /PRNewswire/ -- Blue Spark Technologies, Inc., a global leader in clinical-grade wearable and digital health tech, is launching a first-of-its-kind multi-sensor remote patient monitoring platform, VitalTraq™. VitalTraq includes one of the most groundbreaking contactless vital sign measurement sensors to date, Remote Photoplethysmography (rPPG). Using a simple 30 to 60-second selfie scan, patients, clinicians, and researchers can collect digital measurements, including Heart Rate, Heart Rate Variability, Blood Pressure, and Respiratory Rate vital signs in a single contactless patient experience. 

Key Points: 
  • CLEVELAND, Jan. 25, 2024 /PRNewswire/ -- Blue Spark Technologies, Inc ., a global leader in clinical-grade wearable and digital health tech, is launching a first-of-its-kind multi-sensor remote patient monitoring platform, VitalTraq™ .
  • Using groundbreaking, clinically validated Remote Photoplethysmography technology, patients scan their faces for a reading that captures blood flow patterns and translates them into vital sign measurements in a single remote monitoring platform.
  • "The VitalTraq platform is ideally suited to remote patient monitoring in clinical trials as well as applications such as post-surgical patient monitoring for complications such as sepsis," said John Gannon, President and CEO of Blue Spark Technologies.
  • The VitalTraq remote patient monitoring platform consists of iOS and Android mobile patient applications, the HIPAA-compliant VitalTraq Connect cloud service hosted on the Google Cloud Platform, and a web-based clinical remote monitoring dashboard.

The Inspiration of Innovation, Kieslect Kr2 and Ks2 Smartwatches, Now Available in Malaysia for the First Time

Retrieved on: 
Wednesday, January 17, 2024
Woman, Heart rate, Sleep, GPU, Health, AMOLED, Life, Sunlight, Bluetooth, Prospectus, PPG, PD, FPS, Central processing unit, Oxygen saturation (medicine), KS-2, Shopee, Light-emitting diode, Muses, AOD, Fashion design

The brand officially debuts two fashionable and brilliant smartwatches, the Kieslect Kr2 and Ks2.

Key Points: 
  • The brand officially debuts two fashionable and brilliant smartwatches, the Kieslect Kr2 and Ks2.
  • The award-winning models received the Muse Design Award 2023, Kr2 and the New York Product Design Award 2023, Ks2.
  • Ms. Wei Lee, General Manager of Kieslect Malaysia, said, "Introducing Kr2 and Ks2 by Kieslect, where innovation meets elegance, we are thrilled to bring our cutting-edge technology and timeless design to Malaysia.
  • The ever-stylish Kieslect Kr2 and Ks2 are sure to add the right look and functions to your life.

NTT East Collaborates with Israeli Startup Binah.ai Ltd. for Safety and Health Management Solutions Using Wearable Devices

Retrieved on: 
Tuesday, January 16, 2024
Entrepreneurship, Heart rate, Health, Respiratory rate, Partnership, PPG, Acquisition, Safety, Acceleration, Wireless, Vital signs, Workforce, Blood volume, NTT, HRV, Ageing, Internet of things, Mobile phone

TEL AVIV, Israel, Jan. 16, 2024 /PRNewswire-PRWeb/ -- 

Key Points: 
  • The collaboration's inaugural effort introduces the integration of Binah.ai's proprietary technology, specifically the "Binah Connect", powered by the Binah.ai software, into NTT East's solution "Wearable Connect."
  • This integration is part of the innovative lineup aimed at monitoring employee health and safety to provide peace of mind.
  • NTT Israel (NTT Innovation Laboratory Israel), the focal point of NTT group and its Japanese and global clients to the Israeli innovation eco-system, initiated and facilitated the partnership.
  • While the solution also enables spot measurements using smartphone cameras, continuous monitoring is essential for safety and health management in fieldwork.